Product Overview
Pirtobrutinib | T36287 | TargetMol Chemicals
CAS: 2101700-15-4
Smiles: N/A
Formula: C22H21F4N5O3
Pathway: Angiogenesis|||Tyrosine Kinase/Adaptors
Target: BTK
Receptor: N/A
Bioactivity: Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM[1].
Molecular Weight: 479, 43